Page last updated: 2024-09-05

sorafenib and Nausea

sorafenib has been researched along with Nausea in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's6 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY1
Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A1
Anderson, S; Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Gore, M; Hofilena, G; Hutson, TE; Lathia, C; Negrier, S; Oudard, S; Pena, C; Rolland, F; Shan, M; Stadler, WM; Staehler, M; Szczylik, C1
Blumenschein, GR; Cihon, F; Cupit, L; Fossella, F; Gatzemeier, U; O'Leary, J; Reck, M; Stewart, DJ1
Polliack, A; Tadmor, T; Tallman, MS1
Brandwein, J; Buckstein, R; Crump, M; Eisenhauer, E; Hedley, D; Kamel-Reid, S; Kassis, J; Leber, B; Matthews, J; McIntosh, L; Minden, M; Robinson, S; Seymour, L; Turner, R; Wells, R1
Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S1
Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W1
Burkholder, I; Dittrich, C; Edler, L; Frost, A; Gillessen, S; Hanauske, AR; Hochhaus, A; Morant, R; Mross, K; Scheulen, M; Steinbild, S; Strumberg, D1

Trials

5 trial(s) available for sorafenib and Nausea

ArticleYear
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Gut and liver, 2013, Volume: 7, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Sorafenib; Tomography, Spiral Computed; Venous Thrombosis

2013
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-10, Volume: 27, Issue:20

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Disease-Free Survival; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Nausea; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2009
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2010
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
    British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Fatigue; Humans; Male; Middle Aged; Nausea; Niacinamide; Pain; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome

2007

Other Studies

4 other study(ies) available for sorafenib and Nausea

ArticleYear
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib

2017
Sorafenib - a small molecule with big promise?
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Abdominal Pain; Acute Disease; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fatigue; Humans; Leukemia, Myeloid; Metabolic Clearance Rate; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome

2010
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia

2011
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
    Oncology, 2013, Volume: 84, Issue:1

    Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome; Vomiting

2013